CN117209587A - Application of growth hormone release related polypeptide in preventing and treating immune checkpoint inhibitor related myocarditis - Google Patents
Application of growth hormone release related polypeptide in preventing and treating immune checkpoint inhibitor related myocarditis Download PDFInfo
- Publication number
- CN117209587A CN117209587A CN202311305815.6A CN202311305815A CN117209587A CN 117209587 A CN117209587 A CN 117209587A CN 202311305815 A CN202311305815 A CN 202311305815A CN 117209587 A CN117209587 A CN 117209587A
- Authority
- CN
- China
- Prior art keywords
- myocarditis
- mice
- growth hormone
- group
- ghrl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000009525 Myocarditis Diseases 0.000 title claims abstract description 72
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 39
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 33
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 32
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 32
- 239000000122 growth hormone Substances 0.000 title claims abstract description 32
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 13
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 13
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 13
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 101800001586 Ghrelin Proteins 0.000 claims description 22
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 2
- 150000003839 salts Chemical group 0.000 claims description 2
- 102400000442 Ghrelin-28 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 82
- 230000002107 myocardial effect Effects 0.000 abstract description 32
- 230000008595 infiltration Effects 0.000 abstract description 13
- 238000001764 infiltration Methods 0.000 abstract description 13
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 12
- 210000002966 serum Anatomy 0.000 abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 9
- 206010016654 Fibrosis Diseases 0.000 abstract description 7
- 230000004761 fibrosis Effects 0.000 abstract description 7
- 230000004217 heart function Effects 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 6
- 230000004900 autophagic degradation Effects 0.000 abstract description 5
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 abstract description 4
- 102100022785 Creatine kinase B-type Human genes 0.000 abstract description 4
- 101001047117 Homo sapiens Creatine kinase B-type Proteins 0.000 abstract description 4
- 101000588145 Homo sapiens Microtubule-associated tumor suppressor 1 Proteins 0.000 abstract description 4
- 101000588157 Homo sapiens Microtubule-associated tumor suppressor candidate 2 Proteins 0.000 abstract description 4
- 102100031549 Microtubule-associated tumor suppressor candidate 2 Human genes 0.000 abstract description 4
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 abstract description 4
- 239000006274 endogenous ligand Substances 0.000 abstract description 4
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 abstract description 3
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 208000037891 myocardial injury Diseases 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 239000000854 Human Growth Hormone Substances 0.000 abstract 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 101100514842 Xenopus laevis mtus1 gene Proteins 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 23
- 102000012004 Ghrelin Human genes 0.000 description 21
- 102000004420 Creatine Kinase Human genes 0.000 description 15
- 108010042126 Creatine kinase Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 102100022831 Somatoliberin Human genes 0.000 description 6
- 101710142969 Somatoliberin Proteins 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 5
- 102000004072 Beclin-1 Human genes 0.000 description 5
- 108090000524 Beclin-1 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108010044467 Isoenzymes Proteins 0.000 description 5
- 210000004413 cardiac myocyte Anatomy 0.000 description 5
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 4
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 4
- 102000000393 Ghrelin Receptors Human genes 0.000 description 4
- 108010016122 Ghrelin Receptors Proteins 0.000 description 4
- 102000055207 HMGB1 Human genes 0.000 description 4
- 108700010013 HMGB1 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 4
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000013042 tunel staining Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 3
- HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 3
- 102000003952 Caspase 3 Human genes 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 101150021904 HMGB1 gene Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 102000005157 Somatostatin Human genes 0.000 description 3
- 108010056088 Somatostatin Proteins 0.000 description 3
- 102000004903 Troponin Human genes 0.000 description 3
- 108090001027 Troponin Proteins 0.000 description 3
- 108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 229960000208 pralmorelin Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 3
- 229960000553 somatostatin Drugs 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100164201 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-4 gene Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010059162 Ventricular dyskinesia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 101150096483 atg5 gene Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 108010051768 des-n-octanoyl ghrelin Proteins 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 108010070965 hexarelin Proteins 0.000 description 1
- -1 hmgb1 Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108010088383 interleukin-6 receptor alpha Proteins 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses application of a growth hormone release related polypeptide in preventing and treating myocarditis related to immune checkpoint inhibitor. The growth hormone release related peptide is derived from an endogenous ligand of a human growth hormone secretion receptor, and the amino acid sequence of the endogenous ligand is shown as SEQ ID NO: 1. The growth hormone release related peptide can reduce myocardial injury markers such as CK, CKBB, LDH-1, cTnI and cTnT release in serum of mice with myocarditis related to immune checkpoint inhibitor, reduce inflammatory cell infiltration and fibrosis degree of myocardial tissue, improve cardiac function of the mice with myocarditis, and inhibit apoptosis and autophagy of myocardial cells. When the growth hormone releasing related peptide is used as a medicine component, the invention has the advantages of small molecular weight, low immunogenicity, high specificity, safe action mode, high patentability and the like. The invention provides a new drug choice for treating ICIS-related myocarditis, and has good application prospect.
Description
Technical Field
The invention relates to application of a growth hormone release related polypeptide in preventing and treating immune checkpoint inhibitor related myocarditis, and belongs to the technical field of biological medicines.
Background
Since 2011, the use of immune checkpoint inhibitors (immune checkpoint inhibitors, ICIs) has brought a new choice for advanced malignancy treatment. Clinical data indicate that 1.14% of patients suffer from ICIs-related myocarditis with mortality rates approaching 50%. ICIs-related myocarditis is clinically manifested as chest pain, shortness of breath, pulmonary edema and even cardiogenic shock, and arrhythmia may also occur, leading to syncope and sudden death. Unlike traditional cardiomyopathy, the main pathogenesis of myocarditis associated with immune checkpoint inhibitors is thought to be that immune cells residing around the myocardium are activated to attack normal cardiomyocytes for injury, and pathology is primarily manifested by inflammatory cell infiltration. Whereas traditional ischemic cardiomyopathy is a late manifestation of coronary heart disease, due to loss of cardiomyocytes, fibrosis or scar hyperplasia caused by coronary atherosclerosis. The pathogenesis of the two is different, and the treatment means are also different. Ischemic cardiomyopathy is mainly treated by traditional cardiovascular therapeutic drugs such as digitalis and aminophylline and vasodilators. However, ici s-related myocarditis is mainly treated by high-dose hormone impact, and traditional cardiovascular medicines are almost ineffective for treating the ici s-related myocarditis. However, in clinical practice it has been found that a proportion of patients have reduced clinical benefit due to the occurrence of hormonal resistance, which may eventually progress to MACE (Major Adverse Cardiovascular Events, major cardiovascular adverse events). For this reason, it is urgent to find highly sensitive and specific therapeutic means for ICIs-related myocarditis.
Polypeptides are produced by proteasome degradation and can play an important role as endogenous ligands or receptors mediating a variety of signaling pathways. There are studies showing that the circulating antimicrobial peptide LL-37 has become a novel biomarker in cardiovascular disease in addition to BNP and ANP. Polypeptides also occupy a unique place in the field of drug development, and from early on, to date, hundreds of polypeptide drugs have been approved for sale worldwide. Wherein eptifibatide has been clinically used to treat acute coronary syndrome. Provides a brand new choice for the research and development of polypeptide drugs in the field of cardiovascular diseases.
Growth hormone releasing peptide (ghrelin) is an endogenous ligand for the growth hormone secretagogue receptor (Growth hormone secretagogue receptor, GHSR). ghrelin is found by Kojima et al in mouse and human gastric endocrine cells and hypothalamic arciform nuclei, and is the only natural ligand of GHSR found so far, which contains 28 amino acid residues and has a molecular weight of 33kDa. The ghrelin precursor protein of human and rat consists of 117 amino acids, and the N-terminal pre-23 peptide is characterized by secretion signal peptide; the first 4 amino acid fragments at the N-terminus of ghrelin are the smallest active centers and the P-R structure at the C-terminus (proline-arginine) is the recognition site. Ghrelin differs from ghrelin in humans and rats by only 2 amino acid residues, and the coding gene sequence has 82.9% homology. ghrelin has two secreted forms in vivo: one is that the serine at position 3 of the N-terminal of ghrelin is octanoylated, the other is that this site is not octanoylated. The 3 rd serine of ghrelin is a substantial part of ghrelin that exerts biological functions. Initial studies suggest that the de-octanoylated ghrelin (des-acyl ghrelin) is not biologically active, whereas recent studies have found that both the de-octanoylated and the octanoylated ghrelin are capable of promoting proliferation of spinal nerve epithelium; the de-octanoylated ghrelin has endocrine function, can promote cell proliferation, and has anti-apoptosis effect.
The pulse release of Growth Hormone (GH) at the pituitary is regulated mainly by three factors, hypothalamic growth hormone releasing hormone (growth hormone releasing hormone, GHRH), somatostatin (SS) and ghrelin. Promoting GH secretion, GHRH, SS inhibiting, ghrelin can act synergistically with GHRH to promote the formation of a local neuroendocrine regulatory feedback loop in the hypothalamus. In a system that regulates GH secretion, GHRH binds to its receptor, increasing intracellular levels of cyclic adenosine monophosphate; ghrelin binds to its receptor, K + Depolarization and inhibition of channels, leading to an increase in intracellular IP3 concentration, intracellular Ca 2+ The concentration increases, eventually stimulating GH secretion. The release of GH from pituitary somatotrophic hormone cells may also be controlled by Growth Hormone Releasing Polypeptide (GHRP). A hexapeptide, H-His-D-Trp-Ala-Trp-D-Phe-Lys-CONH, has been found 2 (GHRP-6) regulates the release of growth hormone in somatotrophic hormone cells in a dose dependent manner in several species including humans (bonerset al, endocrinology 1984,114,1537-1545). A subsequent chemical study of GHRP-6 identified other potent growth hormone releasing elements such as GHRP-1, GHRP-2 and Haxarelin (hexarelin) and the like:
GHRP-1：Ala-His-D-(2’)-Nal-Ala-Trp-D-Phe-Lys-NH 2 ；
GHRP-2：D-Ala-D-(2’)-Nal-Ala-Trp-D-Nal-Lys-NH 2 ；
sea sand relin: his-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH 2 。
GHRP-1, GHRP-2, GHRP-6 and Haixorelin are synthetic growth hormone releasing elements (GHS's) which stimulate the secretion of growth hormone by a different mechanism than growth hormone releasing elements.
The present patent (CN 112955165 a) discloses the use of GHRP-6 as a delayed cardioprotector and restorative agent, GHRP-6 being advantageous for reversing cytotoxic events derived from ventricular dyskinesia and diastolic dysfunction in order to reconstruct myocardial function as such and improve perfusion of coronary arteries, myocardium and the rest of the tissues and organs of animals and humans. However, no report is currently available on ghrelin-derived growth hormone release-related polypeptides and their use in the prevention and treatment of immune checkpoint inhibitor-related myocarditis.
Disclosure of Invention
The purpose of the invention is that: aiming at the technical problem of poor curative effect of hormone for treating the ICIs related myocarditis, the invention provides a ghrelin-derived growth hormone release related polypeptide and application thereof in preventing and treating immune checkpoint inhibitor related myocarditis.
In order to achieve the above object, the present invention provides a growth hormone releasing related polypeptide, which is characterized in that the amino acid sequence of the polypeptide is: X-P-Y, wherein P is as shown in SEQ ID NO:1, and X is: NH (NH) 2 Or any one amino acid or any two amino acid combination, Y is: OH or any one amino acid or a combination of any two amino acids.
Preferably, the polypeptide is GHRL-12 having the amino acid sequence as set forth in SEQ ID NO:1 (i.e. X is NH) 2 Y is OH), and the amino acid sequence of the polypeptide is derived from ghrelin protein.
The invention also provides a gene for encoding the growth hormone releasing related polypeptide GHRL-12, which has the nucleotide sequence shown in SEQ ID NO:2, and a nucleotide sequence shown in the following formula.
The invention also provides application of the growth hormone release related polypeptide or pharmaceutically acceptable salt form thereof in preparing medicines for preventing and/or treating immune checkpoint inhibitor related myocarditis.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a method for preparing a medicament for preventing and treating ICIs-related myocarditis by applying ghrelin-derived growth hormone release-related polypeptide GHRL-12 for the first time, and the method is verified on an animal model; in particular, the growth hormone release related polypeptide can reduce the content of CK, CKBB, LDH-1, cTnI and cTnT in mice in the myocarditis group, improve the level of LVEF and FS in mice in the myocarditis group, reduce LVEDs and LVEDd, reduce the infiltration and fibrosis degree of inflammatory cells in myocardial tissues of the mice in the myocarditis group, and obviously inhibit the activation of apoptosis and autophagy key proteins; in addition, the growth hormone release related polypeptide is derived from natural protein, and has the advantages of small molecular weight, small immunogenicity, safe action mode, high patentability and the like when being used as a pharmaceutical component.
Drawings
FIG. 1 is a schematic representation of GHRL-12 in mice with improved ICis-associated myocarditis; A. the mice in each group had a body weight increase every 7 days; B. the heart-to-body ratio of each group of mice; C. the heart-to-shin ratio of each group of mice; * P <0.05, < P <0.01, < P <0.001, one-way ANOVA, n=6.
FIG. 2 shows that GHRL-12 improves cardiac function in mice with ICis-associated myocarditis; a: m-type cardiac ultrasonic images of mice in each experimental group; b: left Ventricular Ejection Fraction (LVEF) statistics for each group of mice; c: left ventricular short axis reduction (FS) statistics for each group of mice; d: end-systole inner diameters (LVEDs) statistics for each group of mice; e: end-diastole inner diameter (LVEDd) statistics for each group of mice; * P <0.05, < P <0.01, < P <0.001, one-way ANOVA, n=6.
FIG. 3 shows that GHRL-12 improves inflammatory cell infiltration and fibrosis in myocardial tissue of mice with ICis-associated myocarditis; a: HE staining results for each group of mice; b: statistics of inflammatory cell infiltration in HE in A with ImageJ; c: masson staining results for each group of mice; d: performing ImageJ statistical analysis on the dyeing result in step C; * P <0.05, < P <0.01, < P <0.001, one-way ANOVA, n=6.
FIG. 4 shows GHRL-12 reduces the release of markers of myocardial injury from mice with ICis-related myocarditis; a: detecting and analyzing results of various groups of mouse Creatine Kinase (CK); b: detection and analysis results of creatine kinase isozymes (Creatine kinase Isoenzyme, CKBB) in serum of each group of mice; c: detection and analysis results of each group of mouse lactate dehydrogenase (Lactate dehydrogenase, LDH) -1; d: detection and analysis results of the troponin (cardiac TroponinI) I of each group of mice; e: detection and analysis results of troponin (cardiac TroponinI) T of each group of mice; * P <0.05, < P <0.01, < P <0.001, one-way ANOVA, n=6.
FIG. 5 shows that GHRL-12 reduces inflammatory factor release in mice with ICis-associated myocarditis; a: results of detection and analysis of interleukin-1β (IL-1β) in serum of each group of mice by ELISA; b: results of detection and analysis of interleukin-6 (IL-6) in serum of each group of mice by ELISA method; c: detection and analysis of the results of tumor necrosis factor-alpha (TNF-alpha) of each group of mice by ELISA; * P <0.05, < P <0.01, < P <0.001, one-way ANOVA, n=6.
FIG. 6 shows that GHRL-12 significantly inhibits apoptosis and activation of autophagy-related proteins in mice with ICis-related myocarditis; A. HMGB1, ATG5, beclin-1 and LC3B protein expression pictures in myocardial tissue of each group of mice; B. statistics of ATG5 protein expression in myocardial tissue of each group of mice; C. the expression statistics of the Beclin-1 protein in the myocardial tissue of each group of mice; D. HMGB1 protein expression statistics in myocardial tissue of each group of mice; E. LC3B protein expression statistics in myocardial tissue of each group of mice; F. myocardial tissue TUNEL staining pictures of each group of mice; G. quantitative results of TUNEL staining of myocardial tissue of each group of mice; H. PARP and caspase-3 protein expression pictures of myocardial tissues of mice in each group; I. the myocardial tissue clear-caspase-3 and caspase-3 protein expression statistics of each group of mice; J. calculating the expression ratio statistics of the clear-PAPRP and PARP proteins of myocardial tissues of each group of mice; * P <0.05, < P <0.01, < P <0.001, one-way ANOVA, n=3.
Detailed Description
In order to make the invention more comprehensible, preferred embodiments accompanied with figures are described in detail below.
The test methods used in the following examples are conventional methods unless otherwise specified; the materials, reagents and the like used, unless otherwise specified, are those commercially available.
Example 1: GHRL-12 polypeptide (i.e. "growth hormone releasing related polypeptide") sequence and preparation thereof
The GHRL-12 polypeptide is synthesized by Shanghai peptide biotechnology company through solid phase chemistry, the purity is more than 95%, the GHRL-12 polypeptide has 12 amino acids, the GHRL-12 polypeptide is positioned at the 12 th-23 th amino acid of human Ghrelin protein, and the amino acid sequence is as follows: val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Pro-Pro-Ala (VQQRKESKKPPA, SEQ ID NO: 1), a nucleotide sequence (SEQ ID NO: 2) of 5'-gtg cag cag aga aag gag agc aag aag ccc cct gcc-3', a molecular Mass (MW) of 1395.62, an isoelectric Point (PI) of 10.29, and an in vivo half-life of more than 20h, indicates that the polypeptide has good drug properties.
Example 2: animal experiment
1. Animal origin:
balb/c mice of 6-8 weeks old, weight 20-25g, supplied by Nanjing Jixiaokang laboratory animal Limited liability company, are raised in the laboratory animal center of the auxiliary Zhongshan hospital at the double denier university.
2. Experimental grouping:
control group (CON group), myocarditis group (ICIs group), GHRL-12group (GHRL-12 group) and GHRL-12+ myocarditis group (GHRL-12+ ICIs group) were given alone. Each group of 6 GHRL-12 polypeptides is administrated according to 10mg/kg, and is prepared into injection by taking physiological saline as solvent and is administrated by tail vein injection.
Establishment of a mice model for myocarditis associated with administration of ghrl-12 and immune checkpoint inhibitor:
mice in the GHRL-12group and the GHRL+myocarditis group are continuously injected with 10mg/kg GHRL-12 for one week by tail vein, and meanwhile, mice in the control group and the myocarditis group have the same volume of nonfunctional scramble peptide by tail vein. Mice in the myocarditis group and the GHRL-12+icis group were given 250 μg cTnI on day 7 and day 14, respectively, and 5mg/kg of anti-PD-1 was intraperitoneally injected 5 times every other day from day 14.
The mice of each group were weighed every 7 days and the general status was recorded.
After one week of model construction, mice were placed in an induction chamber containing 2% isoflurane (Hebei Yi Kagaku, shanghai, china) and continuously supplied with oxygen for 2L/min. After the mice were anesthetized completely, they were lying on an isothermal bench. The heart rate of the mice was maintained at 350-550bpm and M-mode images were recorded.
1mL of orbital vein blood was collected, and the supernatant was collected by conventional centrifugation to determine serum Creatine Kinase (CK), creatine kinase isozyme (CKBB), lactate dehydrogenase (LDH-1), troponin I (cTnI) and troponin T (cTnT) levels; ELISA (enzyme-linked immunosorbent assay) detects the levels of serum inflammatory factors TNF-alpha, IL-1 beta and IL-6.
Heart tissue was sectioned and stained to observe the level of myocarditis cell infiltration and the extent of fibrosis. TUNEL staining is carried out on myocardial tissue, myocardial fibers are stained red by alpha-actinin marks, DAPI staining nuclei are blue, and apoptotic myocardial cells are stained green by TUNEL.
Adding the myocardial tissue blocks into the protein lysate prepared according to the proportion, and extracting tissue proteins. Identification of apoptosis-critical proteins Caspase-3 and PARP and autophagy-critical proteins HMGB1, ATG5, beclin-1 and LC3B expression.
4. Experimental results
(1) GHRL-12 improves the general condition of mice with ICIS-related myocarditis
FIG. 1 shows that the body weight of the mice in the administration group of GHRL-12 alone was not significantly different from the body weight of the mice in the group of gastric lavage physiological saline. While myocarditis mice had insignificant weight gain, showing statistical differences from day 19 (p= 0.0248). On day 31, myocarditis mice with GHRL-12-dry prognosis had more pronounced weight gain, with statistical differences (p=0.0008) from mice in the myocarditis alone group (fig. 1A). After the modeling was completed, the results of measuring the mice' heart rate and heart-to-shin rate revealed that the ICIs group heart rate and heart-to-shin rate were significantly increased and the GHRL-12+ myocarditis group heart rate and heart-to-radius-to-shin rate were significantly decreased compared to the control group and GHRL-12group (fig. 1B and 1C). The results show that GHRL-12 improves the general condition of mice with ICis related myocarditis.
(2) GHRL-12 improves cardiac function of mice with ICIs-related myocarditis
Mice administered with GHRL-12 alone had no significant change in cardiac function, and myocarditis mice had decreased Left Ventricular Ejection Fraction (LVEF) and left ventricular short axis reduction (FS), while LVEF and FS increased to some extent after GHRL-12 intervention (fig. 2B and 2C); meanwhile, myocarditis mice had both elevated left ventricular end-Systole (LVEDs) and left ventricular end-diastole (LVEDd) (p < 0.05), and both had decreased after GHRL-12 intervention (figures 2D and 2E). The results show that GHRL-12 improves the cardiac function of mice with ICis-related myocarditis.
(3) GHRL-12 improves inflammatory cell infiltration and fibrosis of myocardial tissue of mice with ICis-related myocarditis
HE staining results show that the myocardial cells of the mice in the control group and the mice in the GHRL-12group are orderly arranged, the cell morphology is normal, and inflammatory cell infiltration is avoided. Whereas the myocarditis group mice had partially ruptured myocardial tissue, the cell arrangement was disordered, there was significant inflammatory cell infiltration, the myocarditis group mice had reduced myocardial tissue rupture, the myocardial cell arrangement was partially disturbed, and the inflammatory cell infiltration was reduced (fig. 3A). Statistics of inflammatory cell infiltration in HE were performed with ImageJ, and found that there was a statistical difference in the degree of inflammatory cell infiltration in mice with myocarditis compared to the control group (P < 0.05), and in mice with GHRL-12+ myocarditis compared to the myocarditis group (P < 0.05) (fig. 3B). Masson staining showed that mice with myocarditis group had a disturbed myocardial fiber arrangement, and the collagen content was significantly increased compared to the control group and GHRL-12group, while mice with GHRL-12+ myocarditis group had a relatively regular myocardial fiber arrangement, and the myocardial collagen content was significantly reduced (FIG. 3C). The ImageJ analysis showed that there was a statistical difference in the degree of myocardial fiber alignment disorder in mice with myocarditis compared to the collagen content (P < 0.05) and in GHRL-12+ myocarditis compared to the myocarditis (P < 0.05) (fig. 3D). The result shows that GHRL-12 can obviously reduce the inflammatory cell infiltration and the fibrosis degree of the myocardial tissue of mice with the ICis related myocarditis.
(4) GHRL-12 reduces ICIS-related myocarditis mouse myocardial injury zymogram marker release
Creatine Kinase (CK) results showed no significant difference in serum CK values for the GHRL-12 mice compared to the control group, whereas the serum CK values for the myocarditis mice were significantly increased, whereas the serum CK values for the GHRL-12+ myocarditis mice were significantly decreased (fig. 4A). Meanwhile, after a single GHRL-12 dry prognosis, creatine kinase isozymes (Creatine kinase Isoenzyme, CKMB) in the serum of mice were not significantly changed, and CKMB was significantly increased in mice of the myocarditis group, while CKMB was significantly decreased in mice of the GHRL-12+ myocarditis group (fig. 4B). Likewise, GHRL-12 can reduce the release of lactate dehydrogenase (Lactate dehydrogenase, LDH) -1 (fig. 4C). Both murine troponin (cardiac TroponinI) I and T were significantly elevated in the myocarditis group, and GHRL-1 reduced release of murine troponin I and T (fig. 4D and 4E). The result shows that GHRL-12 can obviously reduce the release of myocardial zymogram markers and reduce the damage of ICI to cardiac function.
(5) GHRL-12 reduces inflammatory factor release in mice with ICIs-related myocarditis
ELISA results show that interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha in the serum of the myocarditis mice are obviously increased, and have statistical difference (p < 0.05); serum IL-1β, IL-6 and TNF- α were significantly reduced in mice from the GHRL-12+ myocarditis group and were statistically significant (P < 0.05) compared to the myocarditis group (FIGS. 5A-C). The result shows that GHRL-12 can relieve the damage of ICIs to cardiac muscle, inhibit the overactivation of immune cells and inhibit the release of inflammatory factors.
(6) GHRL-12 improving ICIS-associated myocarditis mice significantly inhibit activation of apoptosis-related proteins and autophagy-related genes
Autophagy key proteins Beclin-1, hmgb1, atg5 and LC3B were all significantly elevated in myocardial tissue of mice in the myocarditis group, but GHRL-12 intervention alone did not affect autophagy. Mice in the GHRL-12+ myocarditis group, beclin-1, HMGB1, ATG5 and LC3B were significantly reduced and had statistical significance (FIGS. 6A-E). TUNEL staining of myocardial tissue showed no significant change in apoptotic cardiomyocytes in the control and GHRL-12 groups. The group of ICIs significantly increased apoptotic cardiomyocytes, while the group of GHRL-12+icis significantly decreased apoptotic cardiomyocytes (fig. 6F-G). Western blotting technique further detects apoptosis-related protein changes, and found that clear-caspase-3 and PARP are significantly activated in myocardial tissue of mice in myocarditis group, while GHRL-12+ myocarditis group is inhibited to a certain extent and has statistical difference (P < 0.05) (FIG. 6E-F). The results indicate that GHRL-12 can inhibit activation of apoptosis and autophagy key proteins.
While the invention has been described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (4)
1. A growth hormone releasing related polypeptide, wherein the amino acid sequence of the polypeptide is: X-P-Y, wherein P is as shown in SEQ ID NO:1, and X is: NH (NH) 2 Or any one amino acid or any two amino acid combination, Y is: OH or any one or any two of amino acidsA combination of amino acids.
2. The growth hormone releasing related polypeptide of claim 1 wherein said polypeptide is GHRL-12 having the amino acid sequence as set forth in SEQ ID NO:1, the amino acid sequence of which is derived from ghrelin protein.
3. A gene encoding the growth hormone releasing related polypeptide of claim 2, wherein said gene has the amino acid sequence as set forth in SEQ ID NO:2, and a nucleotide sequence shown in the following formula.
4. Use of a growth hormone release related polypeptide according to claim 1 or 2, or a pharmaceutically acceptable salt form thereof, for the manufacture of a medicament for the prevention and/or treatment of immune checkpoint inhibitor related myocarditis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311305815.6A CN117209587A (en) | 2023-10-09 | 2023-10-09 | Application of growth hormone release related polypeptide in preventing and treating immune checkpoint inhibitor related myocarditis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311305815.6A CN117209587A (en) | 2023-10-09 | 2023-10-09 | Application of growth hormone release related polypeptide in preventing and treating immune checkpoint inhibitor related myocarditis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117209587A true CN117209587A (en) | 2023-12-12 |
Family
ID=89051112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311305815.6A Pending CN117209587A (en) | 2023-10-09 | 2023-10-09 | Application of growth hormone release related polypeptide in preventing and treating immune checkpoint inhibitor related myocarditis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117209587A (en) |
-
2023
- 2023-10-09 CN CN202311305815.6A patent/CN117209587A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3398961B1 (en) | Triple activator activating glucagon, glp-1 and gip receptor | |
| KR102378943B1 (en) | Pharmaceutical compositions | |
| KR20160142322A (en) | Exendin-4 derivatives as peptidic dual glp-1/glucagon receptor agonists | |
| KR20150096398A (en) | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists | |
| KR20170018433A (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
| KR20180025966A (en) | New Exendin-4 Derivatives as Selective Peptide Double GLP-1 / Glucagon Receptor Agonists | |
| JP2006502100A (en) | Use of a compound having GIP activity for the treatment of disorders associated with abnormal loss of cells and / or for the treatment of obesity | |
| SK147199A3 (en) | Leptin as an inhibitor of tumor cell proliferation | |
| US9149510B2 (en) | Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes | |
| US20200062811A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| CN109475604B (en) | Dosing and use of long-acting CLR/RAMP agonists | |
| US9987333B2 (en) | Method for suppressing malignant tumor metastasis | |
| CN117209587A (en) | Application of growth hormone release related polypeptide in preventing and treating immune checkpoint inhibitor related myocarditis | |
| JP6038795B2 (en) | Pharmaceutical for preventing exacerbation of malignant tumor comprising a combination of natriuretic peptide receptor GC-A agonist and GC-B agonist | |
| US7803768B2 (en) | Method for treatment of hyperglycemia in a subject in need thereof | |
| KR20180102091A (en) | Pharmaceutical preparations for the treatment of diabetes | |
| US20070191275A1 (en) | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments | |
| US20030105009A1 (en) | Polypeptides of covalently linked synthetic bioactive peptide analog(s) for treatment of cancer | |
| WO2008081013A1 (en) | Use of somatostatin analogs in cluster headache | |
| JP2001098000A (en) | New peptide and medicinal use thereof | |
| de Herder | Somatostatin analogs | |
| MX2008010141A (en) | Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes | |
| EA020171B1 (en) | Fused protein, comprising fibroplast growth factor or a fragment thereof and receptor of fibroplast growth factor or a fragment thereof and use of protein for treatment or prophylaxis of diseases or conditions associated with vessels pathology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |